Levine, G.N., D’Amico, A.V., Berger, P., et al. (2010) Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk: A Science Advisory from the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology. Circulation, 121, 833-840.
https://doi.org/10.1161/CIRCULATIONAHA.109.192695

has been cited by the following article:

• TITLE: Cardiac Structure and Function in Men with Prostate Cancer Receiving Androgen-Deprivation Therapy and the Effects of Recreational Small-Sided Football Training: A Randomized Controlled Trial

  AUTHORS: Jakob Friis Schmidt, Lars Juel Andersen, Jacob Uth, Therese Hornstrup, Jesper Christensen, Julie Midtgaard, Klaus Brasso, Peter Krustrup, Mikael Rørth, Peter Riis Hansen

  KEYWORDS: Prostate Cancer, Exercise, Rehabilitation, Cardiovascular

  JOURNAL NAME: World Journal of Cardiovascular Diseases, Vol.7 No.9, September 28, 2017

  ABSTRACT: Purpose: Androgen deprivation therapy (ADT) is a cornerstone in prostate cancer (PCa) management that prolongs PCa-free and overall survival, but effects of ADT on human cardiac function have not been investigated. We used echocardiography to examine cardiac structure and function in patients with prostate cancer receiving ADT and to determine whether an exercise intervention can elicit cardiac adaptations in these subjects. Methods: Forty-three patients with prostate cancer receiving ADT were randomized to 12 weeks football training (ST group; n = 20) or usual care (control [CO] group; n = 23). Cardiac function was assessed at baseline and after 12 weeks by comprehensive echocardiography. Peak oxygen consumption, blood pressure and peripheral microvascular function was also measured. Results: At baseline, no considerable echocardiographic abnormalities were observed. In the ST group, increases in left ventricular diastolic function variables including E/A ratio (P = 0.03), E’ (P = 0.016), E’TDIcolor (P = 0.040) and in left atrial diameter (P = 0.001) were observed after 12 weeks. In addition, diastolic blood pressure (P = 0.027) and resting heart rate (P 0.001) were reduced after ST. In the CO group, no significant changes were observed in the examined variables after 12 weeks. Despite within group changes in the ST group, no significant differences were observed after 12 weeks between groups in echocardiographic variables, peak oxygen consumption, blood pressure and peripheral microvascular function. Conclusion: In men with prostate cancer receiving ADT, echocardiography showed no abnormalities in cardiac structure and function. Twelve weeks of ST failed to elicit significant cardiovascular adaptations and ADT may blunt cardiovascular adaptations to short-term exercise training.